Protagenic Therapeutics Q2 2023 Earnings Report $0.27 +0.01 (+2.12%) As of 02/21/2025 04:00 PM Eastern Earnings History Protagenic Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AProtagenic Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AProtagenic Therapeutics Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call ResourcesPTIX Earnings History Protagenic Therapeutics Earnings HeadlinesPTIX stock touches 52-week low at $0.25 amid sharp annual declineFebruary 11, 2025 | msn.comAvalon Holdings (AMEX:AWX) Stock Quotes, Forecast and News SummaryJanuary 31, 2025 | benzinga.comA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. With the news cycle dominated by the tariffs… Elon’s DOGE… and the Russia peace talks… Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard – in the heart of Appalachia.February 22, 2025 | Porter & Company (Ad)Performance Tech stock hits 52-week low at $0.4January 30, 2025 | msn.comProtagenic Therapeutics faces Nasdaq delisting over equity deficitDecember 5, 2024 | investing.comProtagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 MillionNovember 5, 2024 | finanznachrichten.deSee More Protagenic Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagenic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagenic Therapeutics and other key companies, straight to your email. Email Address About Protagenic TherapeuticsProtagenic Therapeutics (NASDAQ:PTIX), a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.View Protagenic Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
